This is the second trial failure for AbbVie and Roche with Venclexta, which also came up short in the Canova study in patients with relapsed or refractory multiple myeloma who tested positive for ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click here to find out why RHHBY is a Buy.

After establishing Venclexta as a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), AbbVie and Roche were hoping to demonstrate the med's promise in a subset of mul ...

This is not the first clinical setback for Venclexta. In 2023, AbbVie reported that a late-stage study evaluating Venclexta plus dexamethasone in certain multiple myeloma patients also failed to ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first-line option in combination with Roche's Gazyva (obinutuzumab) as a ...

Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, and commercialised by AbbVie outside of ...

Roche Holding AG RHHBY announced new data from the phase III MURANO study on Venclexta/Venclyxto (venetoclax) in patients with previously treated chronic lymphocytic leukemia (CLL) at the American ...

VENCLEXTA targets the BCL-2 protein and works to help restore the process of apoptosis. VENCLEXTA is being developed by AbbVie and Roche.

VENCLEXTA targets the BCL-2 protein and works to help restore the process of apoptosis. 1 VENCLEXTA is being developed by AbbVie and Roche.

AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study June 17, 2025 — 10:30 am EDT Written by Zacks Equity Research for Zacks -> ...